Indomo Secures $25M Funding Round Led by Atomic, Foresite Capital, and Polaris Partners

Why It Matters

The funding accelerates Indomo’s path to market, potentially expanding the at‑home prescription dermatology segment and challenging traditional in‑office skin‑care models. It also signals strong venture confidence in combining pharmaceuticals with innovative delivery technologies in the broader digital‑health landscape.

Deal Summary

Boston‑based therapeutics firm Indomo announced a $25 million financing to advance its Phase 2 trials and device platform. The round was backed by Atomic, Foresite Capital, Polaris Partners and other investors. Funds will support the development of its at‑home acne treatment ClearPen.